Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence

Liver International

Volumn 35, Issue 5, 2015, Pages 1557-1565

  González Colominas, Elena ^a   Broquetas, Teresa ^a,b   Retamero, Alexandra ^a   García Retortillo, Montserrat ^a,b   Cañete, Nuria ^a,b   Coll, Susanna ^a,b   Pellicer, Rosa ^a   Giménez, Maria D ^a,b   Cabrero, Beatriz ^a,b   Bory, Felipe ^a   Knobel, Hernando ^a,b   Salas, Esther ^a   Solà, Ricard ^a,b   Carrión, José A ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

HCV; HIV; Adherence; Drug interactions

Indexed keywords

ABACAVIR; AMLODIPINE; ATORVASTATIN; BOCEPREVIR; CLONAZEPAM; DARUNAVIR; DIAZEPAM; EFAVIRENZ; ESCITALOPRAM; FLUOXETINE; LEVOTHYROXINE SODIUM; LISINOPRIL; LOPINAVIR; METFORMIN; METHADONE; NEVIRAPINE; QUETIAPINE; RAMIPRIL; TELAPREVIR; TENOFOVIR; ZOLPIDEM; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; PROLINE; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; RIBAVIRIN;

ADULT; AGED; ARTICLE; CHARLSON COMORBIDITY INDEX; DEPRESSION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIXED INFECTION; OUTPATIENT CARE; PATIENT COMPLIANCE; PEPTIC ULCER; PREVALENCE; ANALOGS AND DERIVATIVES; COINFECTION; DRUG COMBINATION; DRUG INTERACTION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; MIDDLE AGED; MULTIVARIATE ANALYSIS; STATISTICAL MODEL;

ADULT; AGED; ANTIVIRAL AGENTS; COINFECTION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84927695231     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12729     Document Type: Article

References (29)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
2. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
3. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
4. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
5. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
6. Sulkowski ML, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 86-96.
7. Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV Genotype 1 infection and cirrhosis. Gastroenterology. 2014; 147: 132-42.
8. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55: 1620-8.
9. van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther 2013; 18: 553-60.
10. EASL Recommendations on Treatment of Hepatitis C. J Hepatol 2014; 61: 373-95.
11. Maasoumy B, Port K, Calle Serrano B, et al. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Aliment Pharmacol Ther 2013; 38: 1365-72.
12. Carrion JA, Gonzalez-Colominas E, Garcia-Retortillo M, et al. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. J Hepatol 2013; 59: 926-33.
13. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 2012.
14. University of Liverpool HIV & Hepatitis Pharmacology group Drug Interaction Charts Available at: http://www.hep-druginteractions.org [accessed 01 June 2014].
15. Tseng A.Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatits C. Toronto General Hospital. Available at: http://www.hcvdruginfo.ca [accessed 15 June 2014].
16. ®.EPAR-Product Information. June 2014.
17. ®. EPAR-Product Information. June 2014.
18. Jellin JM GP. Pharmacist's Letter/Prescriber's Letter. Natural Medicines Comprehensive Database. 12th edn. Stockton, CA: Therapeutic Research Faculty, 2009-2010.
19. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
20. Sievert W, Buti M, Agarwal K, et al. Adherence with telaprevir bid vs. q8 h dosing in treatment-naïve HCV-infected patients: results from the Phase III OPTIMIZE Study. The International Liver Congress 2013. J Hepatol 2013; 58: S373. Abstract 905.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
22. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 2007; 39: 2-17.
23. Yovtcheva SP, Rifai MA, Moles JK, Van der Linden BJ. Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics 2001; 42: 411-5.
24. Lauffenburger JC, Mayer CL, Hawke RL, et al. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur J Gastroenterol Hepatol. 2014; 26: 1073-82.
25. Kanter CT, Luin M, Solas C, Burger DM, Vrolijk JM. Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin. Ann Hepatol 2014; 13: 452-5.
26. Van den Eynde E, Ferrer E, Podzamczer D. Acute renal failure and liver toxicity in an HIV/hepatitis C coinfected patient receiving telaprevir and boosted atazanavir. AIDS 2014; 28: 1538-9.
27. Galan RJ, Cidoncha EC, Martin MF, et al. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C. J Manag Care Pharm 2013; 19: 448-53.
28. Juneja M, Euliano R, Satoskar R, Lewis JH. Polypharmacy and comorbidity are associated with a lower early virologic response in hepatitis C patients treated with first generation protease inhibitor triple therapy: a preliminary analysis. Dig Dis Sci 2013; 58: 3348-58.
29. Keating GM. Sofosbuvir: a review of its use in patients with chronic hepatitis C. Drugs 2014; 74: 1127-46.